Abstract:Kidney‑type glutaminase (GLS1) plays a significant role in tumor metabolism. Our recent studies demonstrated that GLS1 was aberrantly expressed in hepatocellular carcinoma (HCC) and facilitated tumor progression. However, the roles of GLS1 in intrahepatic cholangiocarcinoma (ICC) remain largely unknown. Thus, the aim of this study was to evaluate the expression and clinical significance of GLS1 in ICC. For this purpose, combined data from the Oncomine database with those of immunohistochemistry were used to determine the expression levels of GLS1 in cancerous and non‑cancerous tissues. Second, a wound‑healing assay and Transwell assay were used to observe the effects of the knockdown and overexpression of GLS1 on the invasion and migration of ICC cells. We examined the associations between the expression of GLS1 and epithelial‑mesenchymal transition (EMT)‑related markers by western blot analysis. Finally, we examined the associations between GLS1 levels and clinicopathological factors or patient prognosis. The results revealed that GLS1 was overexpressed in different digestive system tumors, including ICC, and that GLS1 expression in ICC tissue was higher than that in peritumoral tissue. The overexpression of GLS1 in RBE cells induced metastasis and invasion. Moreover, the EMT‑related markers, E‑cadherin and Vimentin, were regulated by GLS1 in ICC cells. By contrast, the knockdown of GLS1 expression in QBC939 cells yielded opposite results. Clinically, a high expression of GLS1 in ICC samples negatively correlated with E‑cadherin expression and positively correlated with Vimentin expression. GLS1 protein expression was associated with tumor differentiation (P=0.001) and lymphatic metastasis (P=0.029). Importantly, patients with a high GLS1 expression had a poorer overall survival (OS) and a shorter time to recurrence than patients with a low GLS1 expression. Multivariate analysis indicated that GLS1 expression was an independent prognostic indicator. On the whole, the findings of this study demonstrated that GLS1 is an independent prognostic biomarker of ICC. GLS1 facilitates ICC progression and may thus prove to be a therapeutic target in ICC.

Elevation of Serum Γ-Glutamyltransferase As a Predictor of Aggressive Tumor Behaviors and Unfavorable Prognosis in Patients with Intrahepatic Cholangiocarcinoma

Tumor and Serum Gamma-Glutamyl Transpeptidase, New Prognostic and Molecular Interpretation of an Old Biomarker in Gastric Cancer

High Serum Gamma-Glutamyl Transpeptidase Concentration Associates with Poor Postoperative Prognosis of Patients with Hepatitis B Virus-Associated Intrahepatic Cholangiocarcinoma.

Serum Gamma-Glutamyl Transferase Levels Affect the Prognosis of Patients with Intrahepatic Cholangiocarcinoma Who Receive Postoperative Adjuvant Transcatheter Arterial Chemoembolization: A Propensity Score Matching Study.

Expression of pGSK-3α/β (Tyr279/216) and XIAP proteins in cholangiocarcinoma and their clinical significance

Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization.

Prognostic significance of gamma‐glutamyl transpeptidase to albumin ratio in patients with intrahepatic cholangiocarcinoma after hepatectomy

Model Based on Alkaline Phosphatase and Gamma-Glutamyltransferase for Gallbladder Cancer Prognosis

γ-Glutamyltranspeptidase as a Prognostic Biomarker in Advanced Hepatocellular Carcinoma Treated with Transarterial Chemoembolization

Expression of GLS 1 in Intrahepatic Cholangiocarcinoma and Its Clinical Significance

Albumin to Gamma-Glutamyltransferase Ratio As a Prognostic Indicator in Intrahepatic Cholangiocarcinoma after Curative Resection.

Serum Liver Enzymes Serve As Prognostic Factors in Patients with Intrahepatic Cholangiocarcinoma.

Γ-Glutamyltranspeptidase is a Prognostic Marker of Survival and Recurrence in Radiofrequency-Ablation Treatment of Hepatocellular Carcinoma.

Preoperative Gamma-Glutamyltransferase is Associated with Cancer-Specific Survival and Recurrence-Free Survival of Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus

High GCLC Level in Tumor Tissues is Associated with Poor Prognosis of Hepatocellular Carcinoma after Curative Resection

Elevation of Serum GGT and LDH Levels, Together with Higher BCLC Staging Are Associated with Poor Overall Survival from Hepatocellular Carcinoma: a Retrospective Analysis.

Impact of Serum γ-Glutamyltransferase on Overall Survival in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy

Preoperative Serum Gamma-Glutamyltransferase As a Prognostic Biomarker in Patients Undergoing Radical Cystectomy for Bladder Cancer

Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization

Elevated serum gamma-glutamyltransferase predicts advanced histological liver damage in chronic hepatitis B.

Intrahepatic cholangiocarcinoma: a clinicopathologic study of 37 resected cases